Rubbishing concerns that the increasing FDA scrutiny of Indian pharma companieswas a case of "irrational clampdown", Biocon CMD Kiran Mazumdar-Shaw told CNBC-TV18 that the US regulator is mandating more stringent norms for companies across the world.

Biocon launches second-generation INSUpen EZ

Biocon has launched INSUpen EZ, a second-generation insulin-delivery pen device, developed by Germany‘s Haselmeier. “This is a low-cost pen, which will help us penetrate the market in a bigger way,” CMD Kiran Mazumdar-Shaw told CNBC-TV18‘s Ekta Batra and Nigel D‘Souza.

Biosimilars is the next big thing for generic cos: Biocon

Biocon CMD Kiran Mazumdar-Shaw said the company‘s research efforts are focused on a number of programs that deliver drugs that women can benefit from.

Biocon says confident of maintaining margins in Q4

Third quarter sales for Biocon were lower than street's expectations (Rs 700 crore vs Rs 759 crore) but EBITDA was higher. This was due to margin expansion that resulted from temporary low R&D spend, said Kiran Mazumdar-Shaw. The company would maintain margins in the fourth quarter by changing product mix and focusing on high-margin products.

Don't see immediate revenue impact from Quark deal: Biocon

Biocon has inked a pact with California-based Quark Pharma to co-develop medicines based on the emerging siRNA technology.

To market Roche's cancer drug clone from FY14 end: Biocon

Kiran Mazumdar Shaw, CMD, Biocon says the nod is for India marketing rights but opens up huge opportunities as the cancer drug has a market of USD 6 billion worldwide.

To list clinical research arm after it steadies: Biocon

The biotech major Wednesday reported a better-than-expected 17 percent year-on-year increase in sales for the September quarter, helped by a 46 percent surge in revenues from its clinical research business.

Drug pricing policy issue hurting sector's growth: Biocon

Biotechnology major Biocon which today posted a strong first quarter earnings raised concerns about confusion in the India drug pricing policy which has impacted the growth of the pharma-biotech sector.

Biocon, Mylan in deal for 3 bio-generic insulin drugs

Biocon, a global biopharmaceutical enterprise today entered into a licencing agreement with Mylan for three bio-generic insulin products. Kiran Mazumdar, CMD, Biocon, in an interview to CNBC-TV18, says that the company will receive licencing fees from Mylan, however, they will not receive any milestone payments.

Biocon in pact with Bristol-Myers for 'blockbuster' drug

Biotech major Biocon has signed an option agreement with Bristol-Myers Squibb Company for Biocon‘s IN-105, a prandial oral insulin product candidate.

Looking at insulin biz to drive growth ahead: Biocon

Kiran Mazumdar Shaw, CMD of Biocon said their branded formulation business has grown 45 percent and excluding it the bio pharma business has seen 20 percent growth year-on-year. She also feels the business is gaining traction in emerging markets and the US.

Biocon, Syngene set up 1st nutrition R&D centre

Drug firm Abbott today opened its first nutrition research and development center in the country in collaboration with Biocon's subsidiary Syngene.

No short-term revenue impact from split with Pfizer: Biocon

In an exclusive interview to CNBC-TV18, Kiran Mazumdar Shaw of Biocon says that the breakup with Pfizer will not have any short-term impact on revenues for either company, but will reflect in the fourth quarter financials.

Biocon-Pfizer insulin deal might collapse soon: PharmAsia

The deal between Biocon and Pfizer to market a range of insulin products may be in crisis. Vikas Dandekar, the India Bureau Chief of PharmAsia News who broke this story tells CNBC-TV18 that while sources are saying talks are on to salvage the deal, it is most likely to be called off.

Biocon aims to maintain 35-40% growth in branded healthcare

Bicon aims to maintain its 35-40% growth in its two top business verticals - research services and branded formulations, said CMD Kiran Mazumdar-Shaw in an exclusive interview to CNBC-TV18.

Entrepreneurship lessons from Biocon's Kiran Mazumdar-Shaw

India's largest listed biotechnology firm Biocon's chairperson and managing director Kiran Mazumdar-Shaw is one of India's most successful entrepreneurs.

Rupee depreciation to aid export margins, says Biocon

Biocon chief Kiran Mazumdar-Shaw says that the research division is set to benefit from the fall in the value of rupee. "That apart, Biocon will see margin improvement in exports due to the rate differential," she says.

Real opportunity for Dificid to kick in 3-4 years: Biocon

Kiran Mazumdar, CMD, Biocon in an interview with CNBC-TV18 speaking about the same said that Optimer is planning to launch within the next three- four months. So, in the short-term Biocon will have some contribution to the bottom line from these supplies.

To improve market share, position in Germany: Dr Reddy's

GV Prasad, Vice Chairman and CEO, Dr Reddys Laboratories in an interview with CNBC-TV18 spoke about the quarterly numbers of the company and the road ahead.

NPPA's move to positively impact insulin sales: Biocon

Speaking to CNBC-TV18, Kiran Mazumdar Shaw, chairman and ,managing director of Biocon said," I am glad that NPPA has given us this price increase. It still puts us at a discount to other multinationals and importers of insulin but at least one step at a time."

Clinigene & Syngene may list in a year's time: Biocon

In an exclusive interview with CNBC-TV 18, Kiran Mazumdar Shaw, CMD of Biocon says that Clingene & Syngene to undergo transformation in the business model and would wait for a year before listing the IPO. She also expects Pfizer revenues in the next 24-36 months.